Kohne-WompnerC.H., SchmollH.J., HarstrickA., RustumY.M.: Chemotherapeutic strategies in metastatic colorectal cancer. An overview of current clinical trials. Semin. Oncol., 19(suppl. 3): 105–125, 1992.
2.
ChaneyS.G.: The chemistry and biology of platinum complexes with the 1,2-diaminocyclohexane carrier ligand. Int. J. Oncol., 6: 1291–1305, 1995.
3.
GamelinE., BouilA.L., Boisdron-CelleM., TurcantA., DelvaR., CailleuxA., KrikorianA., BrienzaS., CvitkovicE., RobertJ., LarraF., AllainP.: Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. Clin. Cancer Res., 3: 891–899, 1997.
4.
PendyalaL., CreavenP.J.: In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res., 53: 5970–5976, 1993.
5.
CahillD.P., LengauerC., YuJ., RigginsG.J., WillsonJ.K., MarkowitzS.D., KinzlerK.W., VolgesteinB.: Mutations of mitotic checkpoint genes in human cancers. Nature, 392: 300–303, 1998.
6.
BhattacharyyaN.P., SkandalisA., GaneshA., GrodenJ., MeuthM.: Mutator phenotypes in human colorectal carcinoma cell lines. Proc. Natl. Acad. Sci., 91: 6319–6323, 1994.
7.
FishelR., KolodnerR.D.: Identification of mismatch repair genes and their role in the development of cancer. Curr. Opin. Genet. Dev., 5: 382–395, 1995.
